Cellular immunotherapy for acute myeloid leukemia using dendritic cells that endocytosed autologous leukemic cells

UMIN ID: UMIN000001024

Registered date:12/02/2008

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: acute myeloid leukemia
• Date of first enrollment: 2007/08/01
• Target sample size: 5
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Administer monocyte-derived dendritic cells intradermally every 2 weeks for 5 doses

Outcome(s)

• Primary Outcome: Toxicity of NCI-CTC grade 1-4
• Secondary Outcome: 1. Immunological monitoring 2. Complete remission rate 3. Partial remission rate

Key inclusion & exclusion criteria

• Age minimum: 16years-old
• Age maximum: 79years-old
• Gender: Male and Female
• Exclude criteria: 1. There is deep seated active infection 2. There are other malignancies 3. There are leukemic lesions in the central nervous system 4. There is active autoimmune disease 5. Positive for HBs Ag, HCV Ab, HTLV-I Ab, HIV Ab, or serological test for syphilis 6. Responsible doctors judged the patient inappropriate for the trial

Related Information

• Primary Sponsor: Department of Hematology and Oncology, Kyoto University Hospital
• Source(s) of Monetary Support: Kyoto University Hospital